Warren Eric 4

What Happened

• Warren Eric, Chief Commercial Officer of Mineralys Therapeutics (MLYS), exercised 104,124 stock options and sold the resulting 104,124 shares on June 26, 2026.
• Exercise details: 104,124 shares exercised at $13.24 per share for a total exercise cost of $1,378,602. The shares were sold in the open market at a weighted-average price of $25.90 per share for total proceeds of $2,696,322.
• The Form 4 records the option conversion (derivative disposition) and the immediate sale of the shares, effectively a cashless exercise and sale on the same day.

Key Details

• Transaction date: 2026-06-26; filing date: 2026-06-30 (filed within the standard 2-business-day window).
• Exercise: 104,124 shares @ $13.24 (total exercise cost $1,378,602).
• Sale: 104,124 shares @ weighted-average $25.90 (total proceeds $2,696,322); sale prices ranged $25.8941–$25.9100 per footnote.
• Derivative conversion: 104,124 option shares reported as disposed (recorded at $0) reflecting conversion to common stock and sale.
• Shares owned after the transaction: not disclosed in the filing.
• Footnotes: F1 — transactions effected under a Rule 10b5-1 selling plan adopted March 27, 2026; F2 — weighted-average sale price with per-trade price range available on request; F3 — vesting schedule for the option (25% after one year, then 36 monthly installments).

Context

• This was an option exercise followed by immediate sale (cashless-like outcome) rather than an open-market purchase; sales are often routine or for liquidity rather than a direct signal about company prospects.
• The use of a 10b5-1 plan means the sales were pre-arranged; the filing does not provide evidence of the insider's current view of the stock.